
Jim Greenwood: Thank You and Looking Forward
May 29, 2020
A letter from departing BIO president Jim Greenwood originally sent May 27, 2020
After more than fifteen years as President and CEO of BIO, I will pass the baton to Michelle McMurry-Heath on June 1st. It has been a fascinating period for me and for the biotechnology sector. I am proud of the unparalleled team and the organization I have helped to build and to grow. BIO is a world class advocacy organization that has consistently and effectively advanced the industry and protected it from often intense political and policy pressure.
I have unbounded confidence in the promise of the science and business of biotechnology as long as public policy does not impede innovation.
I believe that two moral precepts must guide public policy. First, no patient should ever lack access to needed medicine because he or she cannot afford what is required to be paid out of pocket and second, no public policy should ever be acceptable if it drives investment away from innovation.
I intend to continue to advocate for these principles as I serve for another year as a consultant to BIO. I also plan to advise and to advocate for individual companies and to serve on two or three boards. If I may be of service, I would be pleased to hear from you.
Thank you for your support for BIO and this transformative industry we have built together.
All the best,
Jim
Jim Greenwood
President & CEO
Biotechnology Innovation Organization (BIO)
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test














